This inventor holds 6 USPTO granted patents. Top assignee: Eisai Company, Limited. Active years: 1989-2001.
Company Filing History:
Years Active: 1989-2001
Title: Yasuo Ishibashi: Innovator in Pharmaceutical Preparations
Introduction
Yasuo Ishibashi is a notable inventor based in Gifu, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of injectable preparations. With a total of 6 patents to his name, Ishibashi's work has had a considerable impact on medical science.
Latest Patents
Ishibashi's latest patents include innovative formulations that enhance the efficacy of medications. One of his notable inventions is a preparation for injection containing lipid A analogs, which provides a method for preparing these analogs in an alkaline aqueous solution. This invention aims to improve the delivery and effectiveness of lipid A analogs in medical treatments. Another significant patent involves injectable preparations containing cephalosporin medicaments. This preparation includes a specific cephalosporin derivative and various excipients, ensuring the stability and effectiveness of the medication.
Career Highlights
Yasuo Ishibashi has built a successful career at Eisai Company, Limited, where he has focused on pharmaceutical innovations. His work has contributed to the advancement of drug formulations, particularly in the area of injectable medications. His expertise in this field has positioned him as a key figure in pharmaceutical research and development.
Collaborations
Throughout his career, Ishibashi has collaborated with esteemed colleagues such as Kazuhide Ashizawa and Sumio Watanabe. These collaborations have fostered a productive environment for innovation and have led to the successful development of various pharmaceutical products.
Conclusion
Yasuo Ishibashi's contributions to the pharmaceutical industry through his patents and innovative work have made a lasting impact. His dedication to improving drug formulations continues to benefit the medical community and patients worldwide.
